DemurisTM is an antibiotic discovery company with unique and world leading expertise in key technologies of genome engineering, natural product sourcing and target-based screening.

Demuris exploits a unique collection of natural product producing actinomycetes

Demuris has acquired a major collection of actinomycete bacteria, unprecedented in its rich diversity, which produce many natural product molecules with therapeutic and industrial importance. The collection is a rich source of starting points for the discovery of a wide range of novel drugs, as well as high value products for the agrochemical, cosmeceutical and industrial enzyme sectors. The company welcomes approaches from potential partners interested in screening for high value products.

World-leading bacterial genomics and antibacterial expertise

Demuris draws on the world leading expertise of Prof Jeff Errington and the unique Centre for Bacterial Cell Biology which is the world’s largest grouping of scientists working on the fundamental biology of bacterial cells. Leading scientists at the Centre have expertise covering almost every important aspect of bacterial cell structure and function. Demuris’ links to the CBCB position the company to take full advantage of the Centre’s pool of knowledge and intellectual resources. Researchers at the CBCB have expertise in many areas of commercial relevance, including antibiotic discovery and target deconvolution, genome engineering, industrial enzymes, etc.

Rich early stage pipeline

Demuris is focused on using its world leading expertise in antibiotic screening technologies to search the actinomycete collection for novel antibiotic leads. The current Product Pipeline includes a collection of over 100 diverse actinomycetes strains with activity against "difficult" Gram negative pathogens, which represent the most important challenge in current antibiotic therapy. Demuris is also in the process of prioritizing from over one thousand anti-Gram-positive activities. The current Lead compound is a broad coverage Gram-positive antibiotic with completely novel structure and mode of action.
Demuris welcomes approaches from potential Pharma or Biotech partners interested in licensing or co-development of one or more programmes.